INSL3 has tumor-promoting activity in thyroid cancer

International Journal of Cancer

Volumn 127, Issue 3, 2010, Pages 521-531

  Hombach Klonisch, Sabine ^a,b   Bialek, Joanna ^c   Radestock, Yvonne ^c   Truong, Anne ^d   Agoulnik, Alexander I ^d,e   Fiebig, Barbara ^c   Willing, Cornelia ^a   Weber, Ekkehard ^c   Hoang Vu, Cuong ^c   Klonisch, Thomas ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Angiogenesis; Human; INSL3; RXFP2; S100A4; Thyroid cancer

Indexed keywords

AGAR; CALVASCULIN; CRE RECOMBINASE; INSULIN LIKE PEPTIDE 3; PEPTIDE HORMONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL MOTILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER; UMBILICAL VEIN; XENOGRAFT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BASE SEQUENCE; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CHILD; DNA PRIMERS; FEMALE; HUMANS; IN SITU NICK-END LABELING; INSULIN; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEINS; RNA, SMALL INTERFERING; S100 PROTEINS; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; YOUNG ADULT;

EID: 77954439887     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25068     Document Type: Article

References (58)

1. Ries Lag MD, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK. SEER cancer statistics review, 1975-2004. Bethesda, MD: Institute NC, 2003.
2. Hombach-Klonisch S, Hoang-Vu C, Kehlen A, Hinze R, Holzhausen HJ, Weber E, Fischer B, Dralle H, Klonisch T. INSL-3 is expressed in human hyperplastic and neoplastic thyrocytes. Int J Oncol 2003;22:993-1001.
3. Pusch W, Balvers M, Ivell R. Molecular cloning and expression of the relaxin-like factor from the mouse testis. Endocrinology 1996;137:3009-13. (Pubitemid 26192198)
4. Adham IM, Burkhardt E, Benahmed M, Engel W. Cloning of a cDNA for a novel insulin-like peptide of the testicular Leydig cells. J Biol Chem 1993;268:26668-72. (Pubitemid 23361751)
5. Bullesbach EE, Schwabe C. LGR8 signal activation by the relaxin-like factor. J Biol Chem 2005;280:14586-90.
6. Bogatcheva NV, Truong A, Feng S, Engel W, Adham IM, Agoulnik AI. GREAT/LGR8 is the only receptor for insulin-like 3 peptide. Mol Endocrinol 2003;17:2639-46.
7. Gorlov IP, Kamat A, Bogatcheva NV, Jones E, Lamb DJ, Truong A, Bishop CE, McElreavey K, Agoulnik AI. Mutations of the GREAT gene cause cryptorchidism. Hum Mol Genet 2002;11:2309-18.
8. Halls ML, Bathgate RA, Summers RJ. Comparison of signaling pathways activated by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes. J Pharmacol Exp Ther 2007;320:281-90.
9. Halls ML, van der Westhuizen ET, Bathgate RA, Summers RJ. Relaxin family peptide receptors - former orphans reunite with their parent ligands to activate multiple signalling pathways. Br J Pharmacol 2007;150:677-91.
10. van der Westhuizen ET, Halls ML, Samuel CS, Bathgate RA, Unemori EN, Sutton SW, Summers RJ. Relaxin family peptide receptors - from orphans to therapeutic targets. Drug Discov Today 2008;13:640-51.
11. Nef S, Parada LF. Cryptorchidism in mice mutant for Insl3. Nat Genet 1999;22:295-9.
12. Zimmermann S, Steding G, Emmen JM, Brinkmann AO, Nayernia K, Holstein AF, Engel W, Adham IM. Targeted disruption of the Insl3 gene causes bilateral cryptorchidism. Mol Endocrinol 1999;13:681-91. (Pubitemid 30645322)
13. Overbeek PA, Gorlov IP, Sutherland RW, Houston JB, Harrison WR, Boettger-Tong HL, Bishop CE, Agoulnik AI. A transgenic insertion causing cryptorchidism in mice. Genesis 2001;30:26-35.
14. Agoulnik AI. Relaxin and related peptides in male reproduction. Adv Exp Med Biol 2007;612:49-64.
15. Silvertown JD, Summerlee AJ, Klonisch T. Relaxin-like peptides in cancer. Int J Cancer 2003;107:513-9.
16. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI. Relaxin promotes prostate cancer progression. Clin Cancer Res 2007;13:1695-702.
17. Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer 2006;118:62-73.
18. Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee AJ, Medin JA. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J 2007;21:754-65.
19. Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC. Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 2006;66:1698-709.
20. Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, DeVere White RW, Kung HJ. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene 2008;27:499-505.
21. Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R, de Vere White RW. The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 2006;25:2082-93.
22. Klonisch T, Muller-Huesmann H, Riedel M, Kehlen A, Bialek J, Radestock Y, Holzhausen HJ, Steger K, Ludwig M, Weidner W, Hoang-Vu C, Hombach-Klonisch S. INSL3 in the benign hyperplastic and neoplastic human prostate gland. Int J Oncol 2005;27:307-15.
23. Hombach-Klonisch S, Bialek J, Trojanowicz B, Weber E, Holzhausen HJ, Silvertown JD, Summerlee AJ, Dralle H, Hoang-Vu C, Klonisch T. Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol 2006;169:617-32.
24. Klonisch T, Mustafa T, Bialek J, Radestock Y, Holzhausen HJ, Dralle H, Hoang-Vu C, Hombach-Klonisch S. Human medullary thyroid carcinoma: a source and potential target for relaxin-like hormones. Ann NY Acad Sci 2005;1041:449-61.
25. Kamat AA, Feng S, Bogatcheva NV, Truong A, Bishop CE, Agoulnik AI. Genetic targeting of relaxin and insulin-like factor 3 receptors in mice. Endocrinology 2004;145:4712-20. (Pubitemid 39281465)
26. Bialek J, Hombach-Klonisch S, Fiebig B, Weber E, Hoang-Vu C, Klonisch T. Lysosomal acid hydrolases of the cathepsin family are novel targets of INSL3 in human thyroid carcinoma cells. Ann NY Acad Sci 2009;1160:361-6.
27. Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska M, Tulchinsky E, Georgiev G, Berezin V, Bock E, Rygaard J, Cao R, Cao Y, et al. The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene 2001;20:4685-95.
28. Tarabykina S, Griffiths TR, Tulchinsky E, Mellon JK, Bronstein IB, Kriajevska M. Metastasis-associated protein S100A4: spotlight on its role in cell migration. Curr Cancer Drug Targets 2007;7:217-28.
29. Muda M, He C, Martini PG, Ferraro T, Layfield S, Taylor D, Chevrier C, Schweickhardt R, Kelton C, Ryan PL, Bathgate RA. Splice variants of the relaxin and INSL3 receptors reveal unanticipated molecular complexity. Mol Hum Reprod 2005;11:591-600.
30. Scott DJ, Layfield S, Yan Y, Sudo S, Hsueh AJ, Tregear GW, Bathgate RA. Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules. J Biol Chem 2006;281:34942-54.
31. Svendsen AM, Vrecl M, Knudsen L, Heding A, Wade JD, Bathgate RA, De Meyts P, Nohr J. Dimerization and negative cooperativity in the relaxin family peptide receptors. Ann NY Acad Sci 2009;1160:54-9.
32. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, Hsueh AJ. Activation of orphan receptors by the hormone relaxin. Science 2002;295:671-4. (Pubitemid 34111824)
33. Rossato M, Barban M, Vettor R. Elevated plasma levels of the novel hormone INSL3 in a woman with metastatic ovarian cancer. Int J Biol Markers 2007;22:159-60. (Pubitemid 47062221)
34. Bay K, Virtanen HE, Hartung S, Ivell R, Main KM, Skakkebaek NE, Andersson AM, Toppari J. Insulin-like factor 3 levels in cord blood and serum from children: effects of age, postnatal hypothalamic-pituitary-gonadal axis activation, and cryptorchidism. J Clin Endocrinol Metab 2007;92:4020-7.
35. Ferlin A, Garolla A, Rigon F, Rasi Caldogno L, Lenzi A, Foresta C. Changes in serum insulin-like factor 3 during normal male puberty. J Clin Endocrinol Metab 2006;91:3426-31.
36. Foresta C, Bettella A, Vinanzi C, Dabrilli P, Meriggiola MC, Garolla A, Ferlin A. A novel circulating hormone of testis origin in humans. J Clin Endocrinol Metab 2004;89:5952-8.
37. Bay K, Hartung S, Ivell R, Schumacher M, Jurgensen D, Jorgensen N, Holm M, Skakkebaek NE, Andersson AM. Insulin-like factor 3 serum levels in 135 normal men and 85 men with testicular disorders: relationship to the luteinizing hormone-testosterone axis. J Clin Endocrinol Metab 2005;90:3410-8.
38. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006;98:1482-93.
39. Kawamura K, Kumagai J, Sudo S, Chun SY, Pisarska M, Morita H, Toppari J, Fu P, Wade JD, Bathgate RA, Hsueh AJ. Paracrine regulation of mammalian oocyte maturation and male germ cell survival. Proc Natl Acad Sci USA 2004;101:7323-8.
40. Lee HY, Zhao S, Fields PA, Sherwood OD. The extent to which relaxin promotes proliferation and inhibits apoptosis of cervical epithelial and stromal cells is greatest during late pregnancy in rats. Endocrinology 2005;146:511-8.
41. Moore XL, Tan SL, Lo CY, Fang L, Su YD, Gao XM, Woodcock EA, Summers RJ, Tregear GW, Bathgate RA, Du XJ. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 2007;148:1582-9.
42. Ferlin A, Pepe A, Gianesello L, Garolla A, Feng S, Giannini S, Zaccolo M, Facciolli A, Morello R, Agoulnik AI, Foresta C. Mutations in the insulin-like factor 3 receptor are associated with osteoporosis. J Bone Miner Res 2008;23:683-93. (Pubitemid 351575022)
43. Radestock Y, Hoang-Vu C, Hombach-Klonisch S. Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells. Breast Cancer Res 2008;10:R71.
44. Radestock Y, Hoang-Vu C, Hombach-Klonisch S. Relaxin downregulates the calcium binding protein S100A4 in MDAMB-231 human breast cancer cells. Ann NY Acad Sci 2005;1041:462-9. (Pubitemid 41132287)
45. Feng S, Bogatcheva NV, Kamat AA, Agoulnik AI. Genetic targeting of relaxin and insl3 signaling in mice. Ann NY Acad Sci 2005;1041:82-90.
46. Zou M, Al-Baradie RS, Al-Hindi H, Farid NR, Shi Y. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer 2005;93:1277-84.
47. Min HS, Choe G, Kim SW, Park YJ, Park do J, Youn YK, Park SH, Cho BY, Park SY. S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid. Mod Pathol 2008;21:748-55.
48. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, Pietrzynski G, Stanimirovic D, Alakhov V. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem 2005;280:20833-41.
49. Schmidt-Hansen B, Ornas D, Grigorian M, Klingelhofer J, Tulchinsky E, Lukanidin E, Ambartsumian N. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 2004;23:5487-95.
50. Ma L, Gao HQ, Li BY, Ma YB, You BA, Zhang FL. Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferators-activated receptor gamma. J Cardiovasc Pharmacol 2007;49:293-8.
51. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003;254:375-85. (Pubitemid 37211261)
52. Heizmann CW, Ackermann GE, Galichet A. Pathologies involving the S100 proteins and RAGE. Subcell Biochem 2007;45:93-138.
53. Yammani RR, Carlson CS, Bresnick AR, Loeser RF. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum 2006;54:2901-11.
54. Kiryushko D, Novitskaya V, Soroka V, Klingelhofer J, Lukanidin E, Berezin V, Bock E. Molecular mechanisms of Ca(2+) signaling in neurons induced by the S100A4 protein. Mol Cell Biol 2006;26:3625-38.
55. Dohchin A, Suzuki JI, Seki H, Masutani M, Shiroto H, Kawakami Y. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma. Cancer 2000;89:482-7.
56. Krueger S, Kellner U, Buehling F, Roessner A. Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype. Cancer Gene Ther 2001;8:522-8.
57. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, Vajkoczy P, Hofmann WK, Peters C, Pennacchio LA, Abolmaali ND, Chavakis E, et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005;11:206-13.
58. Kubota T. Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem 1994;56:4-8. (Pubitemid 24288103)